Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders
About The Study: The results of this randomized clinical trial show that adjunctive semaglutide significantly improved glycemic control and weight outcomes in individuals with schizophrenia spectrum disorders. Secondary outcomes were exploratory. These findings support the use of glucagon-like peptide–1 receptor agonists (GLP-1RAs) as a potential early intervention strategy to reduce cardiometabolic risk in this vulnerable population. […]
